Read by QxMD icon Read

FET PET glioblastoma

Carina Stegmayr, Dennis Oliveira, Nicole Niemietz, Antje Willuweit, Philipp Lohmann, Norbert Galldiks, N Jon Shah, Johannes Ermert, Karl-Josef Langen
PURPOSE: Restoration of the blood-brain barrier (BBB) following antiangiogenic therapy of gliomas using Bevacizumab may result in a decrease of contrast enhancement in magnet resonance imaging (MRI) despite tumor progression. This so called pseudoresponse is difficult to differentiate from true tumor response with conventional MRI. First patient studies have indicated that positron emission tomography (PET) using O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) may be helpful to solve this diagnostic problem...
February 2, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Michael Lundemann, Junia Cardoso Costa, Ian Law, Svend Aage Engelholm, Aida Muhic, Hans Skovgaard Poulsen, Per Munck Af Rosenschold
BACKGROUND AND PURPOSE: To evaluate the patterns of failure following clinical introduction of amino-acid O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET)-PET-guided target definition for radiotherapy (RT) of glioblastoma patients. MATERIALS AND METHODS: The first 66 consecutive patients with confirmed histology, scanned using FET-PET/CT and MRI were selected for evaluation. Chemo-radiotherapy was delivered to a volume based on both MRI and FET-PET (PETvol). The volume of recurrence (RV) was defined on MRI data collected at the time of progression according to RANO criteria...
January 19, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Oliver Oehlke, Michael Mix, Erika Graf, Tanja Schimek-Jasch, Ursula Nestle, Irina Götz, Sabine Schneider-Fuchs, Astrid Weyerbrock, Irina Mader, Brigitta G Baumert, Susan C Short, Philipp T Meyer, Wolfgang A Weber, Anca-Ligia Grosu
BACKGROUND: The higher specificity of amino-acid positron emission tomography (AA-PET) in the diagnosis of gliomas, as well as in the differentiation between recurrence and treatment-related alterations, in comparison to contrast enhancement in T1-weighted MRI was demonstrated in many studies and is the rationale for their implementation into radiation oncology treatment planning. Several clinical trials have demonstrated the significant differences between AA-PET and standard MRI concerning the definition of the gross tumor volume (GTV)...
October 5, 2016: BMC Cancer
Carina Stegmayr, Ulrike Bandelow, Dennis Oliveira, Philipp Lohmann, Antje Willuweit, Christian Filss, Norbert Galldiks, Joachim H R Lübke, N Jon Shah, Johannes Ermert, Karl-Josef Langen
PURPOSE: O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) is an established tracer for the diagnosis of brain tumors with PET. This study investigates the influence of blood-brain barrier (BBB) permeability on (18)F-FET uptake in two rat glioma models and one human xenograft model. METHODS: F98 glioma, 9L gliosarcoma or human U87 glioblastoma cells were implanted into the striatum of 56 Fischer or RNU rats. Thereafter, animals were divided into a control group and a group receiving injections of the glucocorticoid dexamethasone (Dex)...
March 2017: European Journal of Nuclear Medicine and Molecular Imaging
Julie Bolcaen, Kelly Lybaert, Lieselotte Moerman, Benedicte Descamps, Karel Deblaere, Tom Boterberg, Jean-Pierre Kalala, Caroline Van den Broecke, Filip De Vos, Christian Vanhove, Ingeborg Goethals
BACKGROUND: Discrimination between glioblastoma (GB) and radiation necrosis (RN) post-irradiation remains challenging but has a large impact on further treatment and prognosis. In this study, the uptake mechanisms of 18F-fluorodeoxyglucose (18F-FDG), 18F-fluoroethyltyrosine (18F-FET) and 18F-fluoromethylcholine (18F-FCho) positron emission tomography (PET) tracers were investigated in a F98 GB and RN rat model applying kinetic modeling (KM) and graphical analysis (GA) to clarify our previous results...
2016: PloS One
Sidsel Højklint Poulsen, Thomas Urup, Kirsten Grunnet, Ib Jarle Christensen, Vibeke Andrée Larsen, Michael Lundemann Jensen, Per Munck Af Rosenschöld, Hans Skovgaard Poulsen, Ian Law
BACKGROUND: Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-(18)F-fluoroethyl)-L-tyrosine (FET) PET as an independent prognostic biomarker. METHODS: We retrospectively analyzed 146 consecutively treated, newly diagnosed glioblastoma patients. All patients were treated with temozolomide and radiation therapy (RT). CT/MR and FET PET scans were obtained postoperatively for RT planning...
March 2017: European Journal of Nuclear Medicine and Molecular Imaging
Adrien Holzgreve, Matthias Brendel, Song Gu, Janette Carlsen, Erik Mille, Guido Böning, Giorgia Mastrella, Marcus Unterrainer, Franz J Gildehaus, Axel Rominger, Peter Bartenstein, Roland E Kälin, Rainer Glass, Nathalie L Albert
Noninvasive tumor growth monitoring is of particular interest for the evaluation of experimental glioma therapies. This study investigates the potential of positron emission tomography (PET) using O-(2-(18)F-fluoroethyl)-L-tyrosine ([(18)F]-FET) to determine tumor growth in a murine glioblastoma (GBM) model-including estimation of the biological tumor volume (BTV), which has hitherto not been investigated in the pre-clinical context. Fifteen GBM-bearing mice (GL261) and six control mice (shams) were investigated during 5 weeks by PET followed by autoradiographic and histological assessments...
2016: Frontiers in Neuroscience
Maciej Harat, Bogdan Małkowski, Roman Makarewicz
BACKGROUND AND PURPOSE: The diagnostic accuracy of magnetic resonance imaging (MRI) for glioblastoma multiforme (GBM) is suboptimal. We analysed pre-treatment MRI- and dual time-point 18F-fluoroethylthyrosine-PET (FET-PET)-based target volumes and GBM recurrence patterns following radiotherapy with temozolomide. MATERIALS AND METHODS: Thirty-four patients with primary GBM were treated according to MRI-based treatment volumes (GTVRM). Patients underwent dual time-point FET-PET scans prior to treatment, and biological tumour volumes (GTVPET) were contoured but not used for target definition...
August 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Marc D Piroth, Norbert Galldiks, Michael Pinkawa, Richard Holy, Gabriele Stoffels, Johannes Ermert, Felix M Mottaghy, N Jon Shah, Karl-Josef Langen, Michael J Eble
BACKGROUND: O-(2-18 F-fluoroethyl)-L-tyrosine-(FET)-PET may be helpful to improve the definition of radiation target volumes in glioblastomas compared with MRI. We analyzed the relapse patterns in FET-PET after a FET- and MRI-based integrated-boost intensity-modulated radiotherapy (IMRT) of glioblastomas to perform an optimized target volume definition. METHODS: A relapse pattern analysis was performed in 13 glioblastoma patients treated with radiochemotherapy within a prospective phase-II-study between 2008 and 2009...
June 24, 2016: Radiation Oncology
Marco Giovanni Persico, Federica Eleonora Buroni, Francesca Pasi, Lorenzo Lodola, Carlo Aprile, Rosanna Nano, Marina Hodolic
BACKGROUND: Despite complex treatment of surgery, radiotherapy and chemotherapy, high grade gliomas often recur. Differentiation between post-treatment changes and recurrence is difficult. (18)F-methyl-choline ((18)F-FCH) is frequently used in staging and detection of recurrent prostate cancer disease as well as some brain tumours; however accumulation in inflammatory tissue limits its specificity. The (18)F-ethyl-tyrosine ((18)F-FET) shows a specific uptake in malignant cells, resulting from increased expression of amino acid transporters or diffusing through the disrupted blood-brain barrier...
June 1, 2016: Radiology and Oncology
Philip J O'Halloran, Thomas Viel, David W Murray, Lydia Wachsmuth, Katrin Schwegmann, Stefan Wagner, Klaus Kopka, Monika A Jarzabek, Patrick Dicker, Sven Hermann, Cornelius Faber, Tim Klasen, Michael Schäfers, David O'Brien, Jochen H M Prehn, Andreas H Jacobs, Annette T Byrne
PURPOSE: Resistance to bevacizumab (BEV) in glioblastoma is believed to occur via activation of molecular networks including the mTOR/PI3K pathway. Using an MR/PET molecular imaging biomarker approach, we investigated the response to combining BEV with the mTOR/PI3K inhibitor BEZ235. METHODS: Tumours were established by orthotopically implanting U87MG-luc2 cells in mice. Animals were treated with BEZ235 and/or BEV, and imaged using diffusion-weighted-MRI, T2-weighted and T2*-weighted before and after administration of superparamagnetic iron oxide contrast agent...
August 2016: European Journal of Nuclear Medicine and Molecular Imaging
Mette Kjoelhede Nedergaard, Signe Regner Michaelsen, Lara Perryman, Janine Erler, Hans Skovgaard Poulsen, Marie-Thérése Stockhausen, Ulrik Lassen, Andreas Kjaer
BACKGROUND: The radiolabeled amino acid O-(2-(18)F-fluoroethyl)-L-tyrosine (FET) and thymidine analogue 3'-deoxy-3'-(18)F-fluorothymidine (FLT) are widely used for positron emission tomography (PET) brain tumor imaging; however, comparative studies are scarce. The aim of this study therefore was to compare FLT and FET PET for the assessment of anti-VEGF response in glioblastoma xenografts. METHODS: Xenografts with confirmed intracranial glioblastoma were treated with anti-VEGF therapy (B20-4...
March 2016: Nuclear Medicine and Biology
Constantin Lapa, Katharina Lückerath, Irene Kleinlein, Camelia Maria Monoranu, Thomas Linsenmann, Almuth F Kessler, Martina Rudelius, Saskia Kropf, Andreas K Buck, Ralf-Ingo Ernestus, Hans-Jürgen Wester, Mario Löhr, Ken Herrmann
Chemokine receptor-4 (CXCR4) has been reported to be overexpressed in glioblastoma (GBM) and to be associated with poor survival. This study investigated the feasibility of non-invasive CXCR4-directed imaging with positron emission tomography/computed tomography (PET/CT) using the radiolabelled chemokine receptor ligand (68)Ga-Pentixafor. 15 patients with clinical suspicion on primary or recurrent glioblastoma (13 primary, 2 recurrent tumors) underwent (68)Ga-Pentixafor-PET/CT for assessment of CXCR4 expression prior to surgery...
2016: Theranostics
Niels Buchmann, Benjamin Kläsner, Jens Gempt, Jan Stefan Bauer, Thomas Pyka, Claire Delbridge, Bernhard Meyer, Bernd Joachim Krause, Florian Ringel
OBJECTIVE: Complete resection of contrast-enhancing tumor is an important prognostic factor in glioblastoma therapy. The current clinical standard for control of resection is magnetic resonance imaging (MRI). (18)F-Fluoroethyl-l-thyrosine (FET) is a positron emission tomography (PET) radiopharmaceutical applicable for widespread use because of its long half-life radionuclide. We assessed the sensitivity of postoperative MRI versus FET-PET to detect residual tumor and the impact of the time interval between resection and FET-PET...
May 2016: World Neurosurgery
Erik S Mittra, Norman Koglin, Camila Mosci, Meena Kumar, Aileen Hoehne, Khun Visith Keu, Andrei H Iagaru, Andre Mueller, Mathias Berndt, Santiago Bullich, Matthias Friebe, Heribert Schmitt-Willich, Volker Gekeler, Lüder M Fels, Claudia Bacher-Stier, Dae Hyuk Moon, Frederick T Chin, Andrew W Stephens, Ludger M Dinkelborg, Sanjiv S Gambhir
PURPOSE: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) is a novel radiopharmaceutical for Positron Emission Tomography (PET) imaging. It is a glutamate analogue that can be used to measure xC- transporter activity. This study was performed to assess the feasibility of 18F-FSPG for imaging orthotopic brain tumors in small animals and the translation of this approach in human subjects with intracranial malignancies. EXPERIMENTAL DESIGN: For the small animal study, GS9L glioblastoma cells were implanted into brains of Fischer rats and studied with 18F-FSPG, the 18F-labeled glucose derivative 18F-FDG and with the 18F-labeled amino acid derivative 18F-FET...
2016: PloS One
Sied Kebir, Rolf Fimmers, Norbert Galldiks, Niklas Schäfer, Frederic Mack, Christina Schaub, Moritz Stuplich, Michael Niessen, Theophilos Tzaridis, Matthias Simon, Gabriele Stoffels, Karl-Josef Langen, Björn Scheffler, Martin Glas, Ulrich Herrlinger
PURPOSE: Pseudoprogression (PsP) is characterized by therapy-associated but not tumor growth-associated increases of contrast-enhancing glioblastoma lesions on MRI. Although typically occurring during the first 3 months after radiochemotherapy, PsP may occur later in the course of the disease and may then be particularly difficult to distinguish from true tumor progression. We explored PET using O-(2-[(18)F]fluoroethyl)-L-tyrosine ((18)F-FET-PET) to approach the diagnostic dilemma. EXPERIMENTAL DESIGN: Twenty-six patients with glioblastoma that presented with increasing contrast-enhancing lesions later than 3 months after completion of radiochemotherapy underwent (18)F-FET-PET...
May 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Morten Persson, Mette K Nedergaard, Malene Brandt-Larsen, Dorthe Skovgaard, Jesper T Jørgensen, Signe R Michaelsen, Jacob Madsen, Ulrik Lassen, Hans S Poulsen, Andreas Kjaer
UNLABELLED: Glioblastoma is one of the most malignant types of human cancer, and the prognosis is poor. The development and validation of novel molecular imaging biomarkers has the potential to improve tumor detection, grading, risk stratification, and treatment monitoring of gliomas. The aim of this study was to explore the potential of PET imaging of the urokinase-type plasminogen activator receptor (uPAR) in glioblastoma. METHODS: The uPAR messenger RNA expression of tumors from 19 glioblastoma patients was analyzed, and a cell culture derived from one of these patients was used to establish an orthotopic xenograft model of glioblastoma...
February 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Mohammed Jaber, Johannes Wölfer, Christian Ewelt, Markus Holling, Martin Hasselblatt, Thomas Niederstadt, Tarek Zoubi, Matthias Weckesser, Walter Stummer
BACKGROUND: Approximately 20% of grade II and most grade III gliomas fluoresce after 5-aminolevulinic acid (5-ALA) application. Conversely, approximately 30% of nonenhancing gliomas are actually high grade. OBJECTIVE: The aim of this study was to identify preoperative factors (ie, age, enhancement, 18F-fluoroethyl tyrosine positron emission tomography [F-FET PET] uptake ratios) for predicting fluorescence in gliomas without typical glioblastomas imaging features and to determine whether fluorescence will allow prediction of tumor grade or molecular characteristics...
March 2016: Neurosurgery
Per Jensen, Ling Feng, Ian Law, Claus Svarer, Gitte M Knudsen, Jens D Mikkelsen, Robin de Nijs, Vibeke A Larsen, Agnete Dyssegaard, Gerda Thomsen, Walter Fischer, Denis Guilloteau, Lars H Pinborg
UNLABELLED: Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4'-(123)I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT ((123)I-CLINDE) and amino acid transport imaging using O-(2-(18)F-fluoroethyl)-l-tyrosine PET ((18)F-FET) and investigate whether (123)I-CLINDE is superior to (18)F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up. METHODS: Three patients with World Health Organization grade IV GBM were scanned with (123)I-CLINDE SPECT, (18)F-FET PET, and gadolinium-enhanced MR imaging...
September 2015: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Christopher Bell, Nicholas Dowson, Simon Puttick, Yaniv Gal, Paul Thomas, Mike Fay, Jye Smith, Stephen Rose
INTRODUCTION: Despite radical treatment therapies, glioma continues to carry with it a uniformly poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) generally succumb within two years, even those with WHO Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2-5 and 2 years, respectively. PET imaging with (18)F-FDOPA allows in vivo assessment of the metabolism of glioma relative to surrounding tissues. The high sensitivity of (18)F-DOPA imaging grants utility for a number of clinical applications...
October 2015: Nuclear Medicine and Biology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"